Indian Pharmacopoeia Commission,     Ministry of Health and Family Welfare,             
Ghaziabad
,     India    
Publications
        
    - 
      
        
           Reviews   
            
 Current Regulatory and Pharmacopoeial Status of Mycoplasma Testing in Concern with Vaccines Safety for Human Use
 Author(s): Muthusamy Kalaivani*, Priyanka Chaudhary, Anubhuti Goyal and Jai Prakash
 
 Abstract
     Mycoplasma contamination is well known serious microbial contamination that   encountered during the production of biopharmaceutical products produced   from cell culture. Contamination to this biopharmaceuticals represents   potential risk for the health of patients. To minimize this risk monitoring of   mycoplasma contamination is preferred during the manufacturing process in   cell culture substrates. The current methods recommended by United States   Pharmacopoeia, European Pharmacopoeia, British Pharmacopoeia and Indian   Pharmacopoeia for mycoplasma testing of biologics involve cell culture methods   and indicator cell culture method. The conventional methods require long time   period assays (minimum 28 days) and skill for interpretation of the results   which limits the use of these assays. The use of Nucleic Acid Amplification   Test (NAT) technique provides advantages over c..  Read More»